Canntab Therapeutics Ltd
Change company Symbol lookup
Select an option...
CTABF Canntab Therapeutics Ltd
ALIZY Allianz SE
TEO Telecom Argentina SA
BAC Bank of America Corp
TNP Tsakos Energy Navigation Ltd
BFS Saul Centers Inc
ALNY Alnylam Pharmaceuticals Inc
VCNX Vaccinex Inc
XOM Exxon Mobil Corp
ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund
Go


Based in Canada
Company profile

Canntab Therapeutics Limited is a Canada-based phytopharmaceutical company. The Company is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. The Company’s operations comprise a single segment engaged in the medical marijuana business. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. It holds a cannabis standard processing and sales for medical purposes license and a cannabis research license from health Canada.

Closing Price
$0.0109
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0109
Day's Low
0.0109
Volume
(Heavy Day)
Volume:
1,100

10-day average volume:
100
1,100
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.